om 20 capsule
ambee pharmaceuticals ltd. - omeprazole - capsule - 20 mg
om 40 capsule
ambee pharmaceuticals ltd. - omeprazole - capsule - 40 mg
veltassa 16.8g oral powder sachets
vifor pharma uk ltd - patiromer sorbitex calcium - powder - 16.8gram
veltassa 8.4g oral powder sachets
vifor pharma uk ltd - patiromer sorbitex calcium - powder - 8.4gram
veltassa 25.2g sachet powder for oral suspension
om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 25.2 mg
veltassa 16.8g sachet powder for oral suspension
om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 16.8 g
veltassa 8.4g sachet powder for oral suspension
om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 8.4 g
alepam 30 oxazepam 30mg tablet bottle
alphapharm pty ltd - oxazepam, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; quinoline yellow aluminium lake; maize starch; erythrosine aluminium lake - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.
alepam 15 oxazepam 15mg tablet bottle
alphapharm pty ltd - oxazepam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; erythrosine aluminium lake; maize starch; quinoline yellow aluminium lake; lactose monohydrate - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.
suboxone 2/0.5
pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine; naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone - sublingual tablet - 2mg/0.5mg - active: buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone excipient: acesulfame potassium citric acid lactose monohydrate lemon flavour phs-020484 magnesium stearate maize starch mannitol povidone sodium citrate dihydrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included in suboxone to deter intravenous misuse of the product.